Sinovac

The recent controversy over a dengue vaccine has complicated the Philippines’ COVID-19 vaccination program.

Despite cooperating on some aspects, China and Russia are also directly competing for the same vaccine markets - and the national prestige that comes with it.

In the wake of the national security law, public trust in the government has reached new lows. That is inevitably impacting Hong Kong's pandemic response.

China, Russia, and the U.S. are all using vaccines as diplomatic tools, giving a political dimension to other countries’ medical choices.

It is too soon to declare China's government victorious in the race for COVID-19 vaccines.

Gulf states like Bahrain and the UAE are using a Chinese-made COVID-19 vaccine, highlighting a new type of cooperation with China.

The announcement comes as confirmed COVID-19 infections continue to spike across the archipelago.

With its first homegrown vaccine approved for general use, China aims to vaccinate 50 million people by the Lunar New Year in February.

The UAE has officially approved a Sinopharm vaccine, while there are promising unofficial results from Sinovac’s Indonesia trial.

Despite concerns about the vaccines' efficacy, China said it will ensure the products are affordable for developing countries.